IbogaineVault / Portal / Outcomes

Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine

Malcolm, Benjamin J., Polanco, Martin, Barsuglia, Joseph P. · 2018 · Journal of Psychoactive Drugs

Outcomes Observational high

AI-extracted · unverified · confirm at source

Retrospective chart review (N=50): COWS scores ↓ from 8.2 to 3.3, SOWS 20.5 to 10.0, BSCS 6.6 to 1.9 at 48h post-ibogaine (all p<0.01); 78% no clinical withdrawal, 79% minimal cravings; η²=0.54–0.69.

Dosing: 18–20 mg/kg ibogaine HCl (Voacanga-derived, GMP-certified); test dose 100 mg followed by remainder within 2 hours; booster 1–5 mg/kg if post-acute withdrawal at 72h (oral)

Sample size: 50

Contraindications: Prolonged QTc interval, History of heart disease, Severe psychiatric conditions (psychotic spectrum, bipolar I, eating disorders), Pulmonary embolism or deep vein thrombosis, Severe respiratory conditions (emphysema, COPD), Obesity, Gastrointestinal disorders (Crohn's, IBS), Chronic infectious diseases, Cerebellar dysfunction, Organic brain disease or severe TBI, Epilepsy, Current pregnancy, Abnormal electrolytes, Impaired hepatic or renal function, Alcohol, amphetamines, cocaine, or psychiatric medications within 1 week, Buprenorphine or methadone within 4 weeks

View primary source ↗View entry in vault ↗